Biohaven

Biohaven Cash Flow per Share

The Operating Cash Flow per Share of Biohaven (BHVN) as of Oct 21, 2026 is -5.07 USD. In the previous year, Operating Cash Flow per Share was -5.76 USD — a change of -12.02% (higher).

Cash Flow per Share

-5.07USD

YoY

-12.02%

Last updated:

Operating Cash Flow per Share of Biohaven is 2025 -5.07 USD. Operating Cash Flow per Share of Biohaven was 2024 -5.76 USD. It decreases by -12.02% higher compared to the previous year.

The Biohaven Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
-5.03 USD
Jan 1, 2019
-7.19 USD
Jan 1, 2020
-1.57 USD
Jan 1, 2021
-3.70 USD
Jan 1, 2022
-4.89 USD
Jan 1, 2023
-4.15 USD
Jan 1, 2024
-5.76 USD
Jan 1, 2025
-5.07 USD
The Biohaven Cash Flow per Share history
YEARCash Flow per ShareYoY
-5.07USD-12.02%
-5.76USD+38.88%
-4.15USD-15.15%
-4.89USD+32.04%
-3.70USD+136.49%
-1.57USD-78.23%
-7.19USD+43.01%
-5.03USD+92.92%
-2.61USD+115.05%
-1.21USD+423.98%
-0.23USD+385.34%
-0.05USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Operating Cash Flow per Share of Biohaven is -5.07 USD in 2025.

Operating Cash Flow per Share of Biohaven changed from -5.76 USD to -5.07 USD, representing a -12.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Biohaven since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Biohaven

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Biohaven